CA3258109A1 - LIPID NANOPARTICLES BASED ON MULTIPURPOSE MOLECULES FOR THE ADMINISTRATION OF NUCLEIC ACIDS - Google Patents
LIPID NANOPARTICLES BASED ON MULTIPURPOSE MOLECULES FOR THE ADMINISTRATION OF NUCLEIC ACIDSInfo
- Publication number
- CA3258109A1 CA3258109A1 CA3258109A CA3258109A CA3258109A1 CA 3258109 A1 CA3258109 A1 CA 3258109A1 CA 3258109 A CA3258109 A CA 3258109A CA 3258109 A CA3258109 A CA 3258109A CA 3258109 A1 CA3258109 A1 CA 3258109A1
- Authority
- CA
- Canada
- Prior art keywords
- nucleic acid
- lipid nanoparticles
- acid delivery
- molecule based
- based lipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
- C08G73/02—Polyamines
- C08G73/0206—Polyalkylene(poly)amines
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
- C08G73/02—Polyamines
- C08G73/028—Polyamidoamines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22177313.8 | 2022-06-03 | ||
| EP22177313 | 2022-06-03 | ||
| PCT/EP2023/064963 WO2023233042A1 (en) | 2022-06-03 | 2023-06-05 | Polyvalent molecule based lipid nanoparticles for nucleic acid delivery |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3258109A1 true CA3258109A1 (en) | 2023-12-07 |
Family
ID=81940594
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3258109A Pending CA3258109A1 (en) | 2022-06-03 | 2023-06-05 | LIPID NANOPARTICLES BASED ON MULTIPURPOSE MOLECULES FOR THE ADMINISTRATION OF NUCLEIC ACIDS |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250325491A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4531818A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025518282A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20250031158A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119522092A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023278446A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3258109A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL317412A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024014961A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023233042A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250121393A (ko) * | 2022-12-12 | 2025-08-12 | 스타르나 테라퓨틱스 | 표적 전달을 위한 신규 화합물 및 이의 용도 |
| US12343429B2 (en) | 2023-10-05 | 2025-07-01 | Nanovation Therapeutics Inc. | Method of delivery of DNA or RNA cargo unshielded lipid nanoparticles and compositions thereof |
| WO2025245869A1 (zh) * | 2024-05-31 | 2025-12-04 | 清华大学 | 含有精氨酸结构的可电离脂质分子、包含其的脂质纳米颗粒及其用途 |
| CN119431176B (zh) * | 2024-11-05 | 2026-02-13 | 汉信生物科技(苏州)有限公司 | 一种可电离阳离子脂质及其制备方法和应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4995423B2 (ja) * | 2002-12-03 | 2012-08-08 | ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート | 物質を血液−脳関門を渡って輸送するための人工低密度リポタンパク質キャリア |
| EP2279254B1 (en) | 2008-04-15 | 2017-07-05 | Protiva Biotherapeutics Inc. | Novel lipid formulations for nucleic acid delivery |
| KR102764250B1 (ko) | 2015-09-14 | 2025-02-07 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 지질양이온성 덴드리머 및 이의 용도 |
| CN114656378A (zh) * | 2016-05-16 | 2022-06-24 | 得克萨斯州大学系统董事会 | 阳离子磺酰胺氨基脂质和两亲性两性离子氨基脂质 |
| JP7330994B2 (ja) | 2017-11-21 | 2023-08-22 | アイカーン スクール オブ メディスン アット マウント サイナイ | 治療用ナノ生物学的組成物による訓練免疫の促進 |
| CN113616602B (zh) * | 2021-08-31 | 2022-05-10 | 中国药科大学 | 一种重组高密度脂蛋白-聚酰胺-胺纳米复合物、制法及应用 |
-
2023
- 2023-06-05 JP JP2024570980A patent/JP2025518282A/ja active Pending
- 2023-06-05 IL IL317412A patent/IL317412A/en unknown
- 2023-06-05 WO PCT/EP2023/064963 patent/WO2023233042A1/en not_active Ceased
- 2023-06-05 EP EP23731182.4A patent/EP4531818A1/en active Pending
- 2023-06-05 US US18/870,116 patent/US20250325491A1/en active Pending
- 2023-06-05 AU AU2023278446A patent/AU2023278446A1/en active Pending
- 2023-06-05 CN CN202380044712.0A patent/CN119522092A/zh active Pending
- 2023-06-05 CA CA3258109A patent/CA3258109A1/en active Pending
- 2023-06-05 KR KR1020247043050A patent/KR20250031158A/ko active Pending
-
2024
- 2024-12-02 MX MX2024014961A patent/MX2024014961A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024014961A (es) | 2025-01-09 |
| CN119522092A (zh) | 2025-02-25 |
| JP2025518282A (ja) | 2025-06-12 |
| US20250325491A1 (en) | 2025-10-23 |
| EP4531818A1 (en) | 2025-04-09 |
| KR20250031158A (ko) | 2025-03-06 |
| WO2023233042A1 (en) | 2023-12-07 |
| IL317412A (en) | 2025-02-01 |
| AU2023278446A1 (en) | 2024-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL317412A (en) | Lipid nanoparticles based on multifunctional molecules for nucleic acid delivery | |
| IL309502A (en) | Lipid nanoparticles for nucleic acid delivery involving phosphatidylserine | |
| ES2918001B2 (es) | Nanoparticulas lipidicas mejoradas para el suministro de acidos nucleicos | |
| EP4346781A4 (en) | DNA VECTOR DELIVERY USING LIPID NANOPARTICLES | |
| EP4326236A4 (en) | TISSUE-SPECIFIC NUCLEIC ACID DELIVERY BY MIXED CATIONIC LIPID PARTICLES | |
| IL304759A (en) | Lipids suitable for the transfer of nucleic acids | |
| IL281653A (en) | Nanoparticulate Lipid Formulations Including Cationic Lipid Peptides for Nucleic Acid Therapy | |
| CY1125212T1 (el) | Συνθεσεις τροποποιημενου mrna | |
| MX350198B (es) | Emulsiones aceite en agua que contienen acidos nucleicos. | |
| PT2279254T (pt) | Novas formulações lipídicas para entrega de ácido nucleico | |
| WO2012157867A3 (ko) | 초고속 멀티 모드 질량 분석을 위한 비행시간 기반 질량 현미경 시스템 | |
| AU2022296780A1 (en) | Nucleic acid containing nanoparticles | |
| EP4132586A4 (en) | VECTORS FOR EFFICIENT DELIVERY OF NUCLEIC ACIDS | |
| BRPI0922985A2 (pt) | vetor de direcionamento (homing) de receptor de fator de crescimento epidérmico (egfr), método para tratamento de câncer caracterizado por células superexpressando egfr, composição farmacêutica para administração sistêmica. | |
| CL2011002808A1 (es) | Procedimiento para provocar una respuesta inmunitaria en al menos un miembro de las especies aviares que comprende la administracion de una composicion que comprende una molecula de acido nucleico y un vehiculo de liberacion liposomico cationico. | |
| EP4069261A4 (en) | PEPTIDE DOCKING VEHICLE FOR TARGETED NUCLEIC ACID DELIVERY | |
| EP4158042A4 (en) | NUCLEIC ACID CONSTRUCTS FOR PROTEIN PRODUCTION | |
| WO2014134509A3 (en) | Peptide-and amine-modified glucan particles for delivery of therapeutic cargoes | |
| IL325550A (en) | Ionizable dianhydrohexitol-based lipids for nucleic acid transport | |
| AU2024349841A1 (en) | Polymer nanoparticle compositions for non-viral gene delivery | |
| EP4328318A4 (en) | METHODS FOR CHARACTERIZATION OF MOLECULAR RELEASE PARTICLES | |
| HK40112945A (en) | Novel lipid nanoparticles for delivery of nucleic acids | |
| HK40113134A (en) | Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine | |
| HK40108274A (en) | Tissue-specific nucleic acid delivery by mixed cationic lipid particles | |
| CA3278449A1 (en) | Novel ionizable lipid compounds for nucleic acid delivery |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20241202 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250404 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250404 |
|
| R00 | Party data change recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: SMALL ENTITY DECLARATION DETERMINED COMPLIANT Effective date: 20250404 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250404 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250408 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - SMALL Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250530 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250530 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20260225 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS Effective date: 20260225 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260527 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260527 |